Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | KN046 |
| Synonyms | |
| Therapy Description |
KN046 is a bispecific monoclonal antibody that targets PD-L1 (CD274) expressed on tumor cells and CTLA-4 on T lymphocytes, potentially leading to enhanced antitumor immune response (PMID: 37263673). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| KN046 | KN 046|KN-046|Erfonrilimab | CTLA4 Antibody 33 Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 | KN046 is a bispecific monoclonal antibody that targets PD-L1 (CD274) expressed on tumor cells and CTLA-4 on T lymphocytes, potentially leading to enhanced antitumor immune response (PMID: 37263673). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04925947 | Phase II | KN046 | Phase II Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors | Terminated | USA | 0 |